sage-10q_20190630.htm
false Q2 0001597553 --12-31 Large Accelerated Filer false 274486580 true true 274486580 P4Y10M9D P8Y10D P7Y11M23D P6Y10M20D 0001597553 2019-01-01 2019-06-30 xbrli:shares 0001597553 2019-07-31 iso4217:USD 0001597553 2019-06-30 0001597553 2018-12-31 iso4217:USD xbrli:shares 0001597553 us-gaap:ProductMember 2019-04-01 2019-06-30 0001597553 us-gaap:ProductMember 2019-01-01 2019-06-30 0001597553 sage:CollaborationRevenueMember 2019-04-01 2019-06-30 0001597553 sage:CollaborationRevenueMember 2018-04-01 2018-06-30 0001597553 sage:CollaborationRevenueMember 2019-01-01 2019-06-30 0001597553 sage:CollaborationRevenueMember 2018-01-01 2018-06-30 0001597553 2019-04-01 2019-06-30 0001597553 2018-04-01 2018-06-30 0001597553 2018-01-01 2018-06-30 0001597553 2017-12-31 0001597553 2018-06-30 0001597553 us-gaap:CommonStockMember 2017-12-31 0001597553 us-gaap:TreasuryStockMember 2017-12-31 0001597553 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001597553 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001597553 us-gaap:RetainedEarningsMember 2017-12-31 0001597553 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001597553 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0001597553 2018-01-01 2018-03-31 0001597553 us-gaap:TreasuryStockMember 2018-01-01 2018-03-31 0001597553 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0001597553 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001597553 us-gaap:CommonStockMember 2018-03-31 0001597553 us-gaap:TreasuryStockMember 2018-03-31 0001597553 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001597553 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0001597553 us-gaap:RetainedEarningsMember 2018-03-31 0001597553 2018-03-31 0001597553 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0001597553 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0001597553 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-04-01 2018-06-30 0001597553 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0001597553 us-gaap:CommonStockMember 2018-06-30 0001597553 us-gaap:TreasuryStockMember 2018-06-30 0001597553 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001597553 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0001597553 us-gaap:RetainedEarningsMember 2018-06-30 0001597553 us-gaap:CommonStockMember 2018-12-31 0001597553 us-gaap:TreasuryStockMember 2018-12-31 0001597553 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001597553 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001597553 us-gaap:RetainedEarningsMember 2018-12-31 0001597553 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001597553 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001597553 2019-01-01 2019-03-31 0001597553 us-gaap:TreasuryStockMember 2019-01-01 2019-03-31 0001597553 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001597553 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001597553 us-gaap:CommonStockMember 2019-03-31 0001597553 us-gaap:TreasuryStockMember 2019-03-31 0001597553 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001597553 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001597553 us-gaap:RetainedEarningsMember 2019-03-31 0001597553 2019-03-31 0001597553 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001597553 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001597553 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0001597553 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001597553 us-gaap:CommonStockMember 2019-06-30 0001597553 us-gaap:TreasuryStockMember 2019-06-30 0001597553 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001597553 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001597553 us-gaap:RetainedEarningsMember 2019-06-30 0001597553 sage:ConvertibleNotesMember us-gaap:IPOMember us-gaap:RedeemableConvertiblePreferredStockMember 2010-04-16 2019-06-30 0001597553 sage:CydexLicenseAgreementMember 2019-01-01 2019-03-31 0001597553 sage:RegentsOfUniversityOfCaliforniaMember 2019-01-01 2019-03-31 0001597553 2019-01-01 0001597553 us-gaap:CashEquivalentsMember 2019-06-30 0001597553 us-gaap:FairValueInputsLevel1Member us-gaap:CashEquivalentsMember 2019-06-30 0001597553 us-gaap:FairValueInputsLevel1Member 2019-06-30 0001597553 us-gaap:USTreasurySecuritiesMember 2019-06-30 0001597553 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member 2019-06-30 0001597553 us-gaap:CorporateBondSecuritiesMember 2019-06-30 0001597553 us-gaap:CorporateBondSecuritiesMember us-gaap:FairValueInputsLevel2Member 2019-06-30 0001597553 sage:InternationalCorporateBondsMember 2019-06-30 0001597553 sage:InternationalCorporateBondsMember us-gaap:FairValueInputsLevel2Member 2019-06-30 0001597553 us-gaap:CommercialPaperMember 2019-06-30 0001597553 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member 2019-06-30 0001597553 sage:InternationalCommercialPaperMember 2019-06-30 0001597553 sage:InternationalCommercialPaperMember us-gaap:FairValueInputsLevel2Member 2019-06-30 0001597553 us-gaap:FairValueInputsLevel2Member 2019-06-30 0001597553 us-gaap:CashEquivalentsMember 2018-12-31 0001597553 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0001597553 us-gaap:FairValueInputsLevel1Member 2018-12-31 0001597553 us-gaap:USTreasurySecuritiesMember 2018-12-31 0001597553 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2018-12-31 0001597553 us-gaap:CorporateBondSecuritiesMember 2018-12-31 0001597553 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateBondSecuritiesMember 2018-12-31 0001597553 sage:InternationalCorporateBondsMember 2018-12-31 0001597553 us-gaap:FairValueInputsLevel2Member sage:InternationalCorporateBondsMember 2018-12-31 0001597553 us-gaap:CommercialPaperMember 2018-12-31 0001597553 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember 2018-12-31 0001597553 sage:InternationalCommercialPaperMember 2018-12-31 0001597553 us-gaap:FairValueInputsLevel2Member sage:InternationalCommercialPaperMember 2018-12-31 0001597553 us-gaap:FairValueInputsLevel2Member 2018-12-31 0001597553 srt:MaximumMember 2019-01-01 2019-06-30 0001597553 srt:MaximumMember 2018-01-01 2018-12-31 sage:MarketableSecurity 0001597553 us-gaap:CorporateBondSecuritiesMember 2018-01-01 2018-12-31 0001597553 srt:MinimumMember 2019-01-01 2019-06-30 0001597553 2018-01-01 2018-12-31 0001597553 sage:ComputerHardwareAndSoftwareMember 2019-06-30 0001597553 sage:ComputerHardwareAndSoftwareMember 2018-12-31 0001597553 us-gaap:FurnitureAndFixturesMember 2019-06-30 0001597553 us-gaap:FurnitureAndFixturesMember 2018-12-31 0001597553 us-gaap:LeaseholdImprovementsMember 2019-06-30 0001597553 us-gaap:LeaseholdImprovementsMember 2018-12-31 0001597553 sage:ComputerHardwareAndSoftwareMember 2019-01-01 2019-06-30 0001597553 us-gaap:FurnitureAndFixturesMember 2019-01-01 2019-06-30 utr:sqft 0001597553 sage:OperatingLeaseOneMember 2019-06-29 2019-06-30 0001597553 sage:OperatingLeaseTwoMember 2018-01-01 2018-03-31 0001597553 sage:OperatingLeaseTwoMember 2019-01-01 2019-06-30 0001597553 sage:OperatingLeaseTwoMember 2018-04-01 2018-04-30 0001597553 sage:OperatingLeaseTwoMember 2018-08-01 2018-08-01 0001597553 sage:OperatingLeaseTwoMember 2018-10-01 2018-10-02 0001597553 sage:OperatingLeaseThreeMember 2018-05-01 2018-05-31 0001597553 sage:OperatingLeaseOneMember 2018-09-29 2018-09-30 0001597553 sage:OperatingLeaseOneMember 2018-10-01 2018-10-31 0001597553 sage:OperatingLeaseOneMember 2019-03-01 2019-03-31 0001597553 sage:OperatingLeaseOneMember 2019-02-28 2019-02-28 0001597553 sage:OperatingLeaseFiveMember 2018-12-01 2018-12-31 0001597553 us-gaap:AccountingStandardsUpdate201602Member 2019-06-30 xbrli:pure 0001597553 sage:CydexLicenseAgreementMember 2019-01-01 2019-06-30 0001597553 sage:FirstAndSecondClinicalDevelopmentMilestonesMember srt:MaximumMember sage:CydexLicenseAgreementMember sage:LicenseOneMember 2019-06-30 0001597553 sage:FirstAndSecondRegulatoryMilestonesMember srt:MaximumMember sage:CydexLicenseAgreementMember sage:LicenseOneMember 2019-06-30 0001597553 sage:ThirdAndFourthClinicalDevelopmentMilestonesMember srt:MaximumMember sage:CydexLicenseAgreementMember sage:LicenseOneMember 2019-06-30 0001597553 sage:ThirdAndFourthRegulatoryMilestonesMember srt:MaximumMember sage:CydexLicenseAgreementMember sage:LicenseOneMember 2019-06-30 0001597553 sage:ClinicalDevelopmentMilestonesMember srt:MaximumMember sage:CydexLicenseAgreementMember sage:LicenseTwoMember 2019-06-30 0001597553 sage:RegulatoryMilestonesMember srt:MaximumMember sage:CydexLicenseAgreementMember sage:LicenseTwoMember 2019-06-30 0001597553 sage:ClinicalDevelopmentAndRegulatoryMilestoneMember sage:CydexLicenseAgreementMember 2019-01-01 2019-06-30 0001597553 sage:ClinicalDevelopmentAndRegulatoryMilestoneMember sage:CydexLicenseAgreementMember 2019-06-30 0001597553 sage:CydexLicenseAgreementMember sage:RegulatoryMilestonesMember sage:LicenseOneMember 2019-06-30 0001597553 sage:CydexLicenseAgreementMember sage:RegulatoryMilestonesMember sage:LicenseOneMember 2019-01-01 2019-06-30 0001597553 sage:CydexLicenseAgreementMember sage:RegulatoryMilestonesMember sage:LicenseOneMember 2019-04-01 2019-06-30 0001597553 sage:CydexLicenseAgreementMember sage:RegulatoryMilestonesMember sage:LicenseOneMember 2018-01-01 2018-06-30 0001597553 sage:CydexLicenseAgreementMember sage:RegulatoryMilestonesMember sage:LicenseOneMember 2018-04-01 2018-06-30 0001597553 sage:CydexLicenseAgreementMember sage:ClinicalDevelopmentMilestonesMember sage:LicenseOneMember 2019-04-01 2019-06-30 0001597553 sage:ClinicalDevelopmentMilestonesMember sage:UniversityOfCaliforniaLicenseAgreementsMember 2015-12-30 2015-12-31 0001597553 sage:ClinicalDevelopmentMilestonesMember srt:MaximumMember sage:UniversityOfCaliforniaLicenseAgreementsMember 2015-12-30 2015-12-31 0001597553 sage:ScenarioOneMember sage:UniversityOfCaliforniaLicenseAgreementsMember 2015-12-30 2015-12-31 0001597553 sage:ScenarioTwoMember sage:UniversityOfCaliforniaLicenseAgreementsMember 2015-12-30 2015-12-31 0001597553 sage:UniversityOfCaliforniaLicenseAgreementsMember 2015-06-01 2015-06-30 0001597553 sage:UniversityOfCaliforniaLicenseAgreementsMember 2015-01-01 2015-12-31 0001597553 sage:UniversityOfCaliforniaLicenseAgreementsMember sage:RegulatoryMilestonesMember srt:MaximumMember 2015-06-30 0001597553 sage:UniversityOfCaliforniaLicenseAgreementsMember sage:SalesMilestonesMember srt:MaximumMember 2015-06-30 0001597553 sage:UniversityOfCaliforniaLicenseAgreementsMember sage:RegulatoryAndSalesMilestonesMember 2019-01-01 2019-06-30 0001597553 sage:UniversityOfCaliforniaLicenseAgreementsMember sage:RegulatoryAndSalesMilestonesMember 2019-06-30 0001597553 sage:UniversityOfCaliforniaLicenseAgreementsMember sage:RegulatoryMilestonesMember 2019-06-30 0001597553 sage:UniversityOfCaliforniaLicenseAgreementsMember sage:RegulatoryMilestonesMember 2019-01-01 2019-06-30 0001597553 sage:UniversityOfCaliforniaLicenseAgreementsMember 2018-04-01 2018-06-30 0001597553 sage:UniversityOfCaliforniaLicenseAgreementsMember 2018-01-01 2018-06-30 0001597553 sage:UniversityOfCaliforniaLicenseAgreementsMember 2019-04-01 2019-06-30 0001597553 sage:WashingtonUniversityLicenseAgreementMember 2013-11-01 2013-11-30 0001597553 sage:WashingtonUniversityLicenseAgreementMember 2013-01-01 2013-12-31 0001597553 sage:WashingtonUniversityLicenseAgreementMember srt:MaximumMember sage:ClinicalDevelopmentMilestonesMember 2013-11-30 0001597553 sage:WashingtonUniversityLicenseAgreementMember srt:MaximumMember sage:RegulatoryMilestonesMember 2013-11-30 0001597553 sage:WashingtonUniversityLicenseAgreementMember sage:ClinicalDevelopmentMilestonesMember 2019-01-01 2019-06-30 0001597553 sage:WashingtonUniversityLicenseAgreementMember 2019-04-01 2019-06-30 0001597553 sage:WashingtonUniversityLicenseAgreementMember 2019-01-01 2019-06-30 0001597553 sage:WashingtonUniversityLicenseAgreementMember 2018-04-01 2018-06-30 0001597553 sage:WashingtonUniversityLicenseAgreementMember 2018-01-01 2018-06-30 0001597553 sage:ConsultingAgreementMember sage:ClinicalDevelopmentAndRegulatoryMilestoneMember srt:MaximumMember 2014-01-31 0001597553 sage:ConsultingAgreementMember sage:ClinicalDevelopmentAndRegulatoryMilestoneMember 2014-01-01 2014-01-31 0001597553 sage:ConsultingAgreementMember sage:ClinicalDevelopmentAndRegulatoryMilestoneMember 2019-01-01 2019-06-30 0001597553 sage:ConsultingAgreementMember 2019-04-01 2019-06-30 0001597553 sage:ConsultingAgreementMember 2019-01-01 2019-06-30 0001597553 sage:ConsultingAgreementMember 2018-04-01 2018-06-30 0001597553 sage:ConsultingAgreementMember 2018-01-01 2018-06-30 0001597553 sage:ShionogiCollaborationAgreementMember sage:LicenseThreeMember 2018-06-11 2018-06-12 0001597553 sage:ShionogiCollaborationAgreementMember srt:MaximumMember sage:LicenseThreeMember 2018-06-12 0001597553 sage:ShionogiCollaborationAgreementMember srt:MaximumMember sage:LicenseThreeMember sage:RegulatoryMilestonesMember 2018-06-11 2018-06-12 0001597553 sage:ShionogiCollaborationAgreementMember srt:MaximumMember sage:LicenseThreeMember sage:CommercialMilestonesMember 2018-06-11 2018-06-12 0001597553 sage:ShionogiCollaborationAgreementMember srt:MaximumMember sage:LicenseThreeMember sage:SalesMilestonesMember 2018-06-11 2018-06-12 0001597553 sage:ShionogiCollaborationAgreementMember sage:LicenseThreeMember 2019-06-30 0001597553 sage:ShionogiCollaborationAgreementMember sage:LicenseThreeMember 2019-01-01 2019-06-30 0001597553 2018-02-12 2018-02-13 0001597553 2018-02-13 0001597553 2019-02-26 2019-02-27 0001597553 2019-02-27 0001597553 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-03-31 0001597553 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2017-01-01 2017-03-31 0001597553 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2017-01-01 2017-03-31 0001597553 sage:PerformanceRestrictedStockUnitsMember 2018-01-01 2018-03-31 0001597553 sage:PerformanceRestrictedStockUnitsMember sage:CommercialMilestonesMember 2018-04-01 2018-06-30 0001597553 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-06-30 0001597553 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-06-30 0001597553 us-gaap:RestrictedStockUnitsRSUMember 2019-04-01 2019-06-30 0001597553 us-gaap:RestrictedStockUnitsRSUMember 2018-04-01 2018-06-30 0001597553 sage:PerformanceRestrictedStockUnitsMember 2019-01-01 2019-06-30 0001597553 sage:PerformanceRestrictedStockUnitsMember 2019-04-01 2019-06-30 0001597553 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0001597553 us-gaap:RestrictedStockUnitsRSUMember 2019-06-30 0001597553 sage:TwoThousandElevenStockOptionPlanMember 2019-01-01 2019-06-30 0001597553 sage:TwoThousandFourteenStockOptionPlanMember srt:MaximumMember 2018-01-01 2018-12-31 0001597553 sage:TwoThousandFourteenStockOptionPlanMember 2019-01-01 2019-01-01 0001597553 sage:TwoThousandSixteenStockOptionPlanMember 2018-09-20 0001597553 us-gaap:PerformanceSharesMember 2018-04-01 2018-06-30 0001597553 us-gaap:PerformanceSharesMember 2018-01-01 2018-06-30 0001597553 us-gaap:PerformanceSharesMember 2019-01-01 2019-06-30 sage:Milestone 0001597553 sage:PerformanceBasedStockOptionsMember 2019-01-01 2019-03-31 0001597553 sage:PerformanceBasedStockOptionsMember 2018-01-01 2018-06-30 0001597553 sage:PerformanceBasedStockOptionsMember 2019-04-01 2019-06-30 0001597553 sage:PerformanceBasedStockOptionsMember 2018-01-01 2018-12-31 0001597553 sage:PerformanceBasedStockOptionsMember 2017-01-01 2017-12-31 0001597553 sage:CommercialMilestonesMember 2019-04-01 2019-06-30 0001597553 sage:CommercialMilestonesMember 2019-01-01 2019-06-30 0001597553 sage:PerformanceBasedStockOptionsMember sage:ConsultantMember 2018-04-01 2018-06-30 0001597553 us-gaap:ResearchAndDevelopmentExpenseMember 2019-04-01 2019-06-30 0001597553 us-gaap:ResearchAndDevelopmentExpenseMember 2018-04-01 2018-06-30 0001597553 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-06-30 0001597553 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-06-30 0001597553 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-04-01 2019-06-30 0001597553 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-04-01 2018-06-30 0001597553 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-06-30 0001597553 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-06-30 0001597553 us-gaap:EmployeeStockOptionMember 2019-04-01 2019-06-30 0001597553 us-gaap:EmployeeStockOptionMember 2018-04-01 2018-06-30 0001597553 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-06-30 0001597553 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-06-30 0001597553 sage:EmployeeStockPurchasePlanMember 2019-04-01 2019-06-30 0001597553 sage:EmployeeStockPurchasePlanMember 2018-04-01 2018-06-30 0001597553 sage:EmployeeStockPurchasePlanMember 2019-01-01 2019-06-30 0001597553 sage:EmployeeStockPurchasePlanMember 2018-01-01 2018-06-30 0001597553 us-gaap:EmployeeStockOptionMember 2018-12-31 0001597553 us-gaap:EmployeeStockOptionMember 2019-06-30 0001597553 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0001597553 us-gaap:PerformanceSharesMember 2019-06-30 0001597553 us-gaap:EmployeeStockOptionMember 2019-04-01 2019-06-30 0001597553 us-gaap:EmployeeStockOptionMember 2018-04-01 2018-06-30 0001597553 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-06-30 0001597553 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-06-30 0001597553 us-gaap:RestrictedStockUnitsRSUMember 2018-04-01 2018-06-30 0001597553 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-06-30 0001597553 sage:EmployeeStockPurchasePlanMember 2019-04-01 2019-06-30 0001597553 sage:EmployeeStockPurchasePlanMember 2018-04-01 2018-06-30 0001597553 sage:EmployeeStockPurchasePlanMember 2019-01-01 2019-06-30 0001597553 sage:EmployeeStockPurchasePlanMember 2018-01-01 2018-06-30

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2019

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

Commission file number: 001-36544

 

Sage Therapeutics, Inc.

(Exact name of registrant as specified in its Charter)

 

 

 

Delaware

27-4486580

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

215 First Street

Cambridge, Massachusetts 02142

(Address of principal executive office) (Zip Code)

Registrant’s telephone number, including area code: (617) 299-8380

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

SAGE

The Nasdaq Global Market

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company and emerging growth company in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

Accelerated filer

 

 

 

 

 

Non-accelerated filer

 

Smaller reporting company

Emerging Growth Company

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

As of July 31, 2019, there were 51,656,993 shares of the registrant’s common stock, $0.0001 par value per share, outstanding.

 

 

 

 

 


 

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q, or Quarterly Report, contains forward-looking statements that involve risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this Quarterly Report are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “expects”, “intends”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, “continue” or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:

 

our view as to potential future results of our ongoing commercialization efforts in the U.S. with respect to ZULRESSO™ (brexanolone) injection which is approved in the U.S. for the treatment of postpartum depression, or PPD, including our expectations with respect to: future revenues and sales momentum; the number of patients who may receive ZULRESSO for the treatment of PPD; the availability and willingness of healthcare settings to administer ZULRESSO; the scope, level and availability of reimbursement, including reimbursement for costs incurred by the healthcare settings that administer ZULRESSO, reimbursement of cost of treatment to the patient, and the nature of any limitations imposed by payors; and the level of market acceptance of ZULRESSO as a treatment for PPD by healthcare settings, prescribers and women suffering from PPD.

 

our expectations as to the sufficiency of our planned development program for SAGE-217 in major depressive disorder and PPD, if successful, to support filing of a New Drug Application, or NDA, with the FDA; our statements regarding the potential for approval of SAGE-217 in such indications in the U.S.; our plans and expectations for development of SAGE-217 in additional indications; our plans and expectations for commercialization of SAGE-217 and our view of the potential product profile, market impact, market size and opportunity for SAGE-217, if successfully developed and approved.

 

our plans to develop SAGE-324, SAGE-718 and our other product candidates in the central nervous system, or CNS, disorders we discuss in this Quarterly Report, and potentially in other indications and our view of the potential product profile and treatment paradigm impact for such product candidates, if successfully developed and approved;

 

our ability, within the expected time-frames, to initiate clinical trials and non-clinical studies of existing or future product candidates, including pivotal clinical trials, and to successfully complete and announce the results of ongoing or future clinical trials;

 

our plans and potential outcomes with respect to other research and development activities and our business development efforts;

 

our plans and expectations with respect to the potential development of any product or product candidate for markets outside the U.S.;

 

our estimates regarding expenses, use of cash and projected cash on hand at any given timepoint, timing of future cash needs, and capital requirements;

 

our expectations as to the amount of future revenues that may be achieved;

 

our expectations with respect to the availability of supplies of ZULRESSO and our product candidates, and the expected performance of our third-party manufacturers;

 

our ability to obtain and maintain intellectual property protection for our proprietary assets and other forms of exclusivity relevant to our business;

2


 

 

the estimated number of patients with diseases or disorders of interest to us; the potential size of the market for ZULRESSO in PPD and for our product candidates in the indications we are studying or plan to study; the potential for ZULRESSO as a treatment for PPD and current or future product candidates, if successfully developed and approved, in the markets for which they are approved; and our ability to serve those markets;

 

the level of costs we may incur in connection with our activities, the possible timing and sources of future financings, and our ability to obtain additional financing when needed to fund future operations;

 

the potential for success of competing products that are or become available for PPD or any of the indications that we are pursuing or may pursue in the future with our product candidates;

 

the potential risk of loss of key scientific or management personnel; and

 

other risks and uncertainties, including those listed under Part II, Item 1A, Risk Factors.

Any forward-looking statements in this Quarterly Report reflect our current views with respect to future events and with respect to our business and future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those described under Part II, Item 1A, Risk Factors and elsewhere in this Quarterly Report. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

We may from time to time provide estimates, projections and other information concerning our industry, the general business environment, and the markets for certain diseases, including estimates regarding the potential size of those markets and the estimated incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events, circumstances or numbers, including actual disease prevalence rates and market size, may differ materially from the information reflected in this Quarterly Report. Unless otherwise expressly stated, we obtained this industry, business information, market data, prevalence information and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties; industry, medical and general publications; government data; and similar sources, in some cases applying our own assumptions and analysis that may, in the future, prove not to have been accurate.

 

 

3


 

Sage Therapeutics, Inc.

INDEX

 

 

 

 

 

Page

PART I – FINANCIAL INFORMATION

 

 

 

 

 

 

 

Item 1.

 

Financial Statements (Unaudited)

 

5

 

 

Condensed Consolidated Balance Sheets as of June 30, 2019 and December 31, 2018

 

5

 

 

Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2019 and 2018

 

6

 

 

Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2019 and 2018

 

7

 

 

Consolidated Statements of Changes in Stockholders’ Equity for the three and six months ended June 30, 2019 and 2018

 

8

 

 

Notes to Condensed Consolidated Financial Statements

 

9

Item 2.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

29

Item 3.

 

Quantitative and Qualitative Disclosures About Market Risk

 

49

Item 4.

 

Controls and Procedures

 

50

 

 

 

PART II – OTHER INFORMATION

 

 

 

 

 

 

 

Item 1.

 

Legal Proceedings

 

51

Item 1A.

 

Risk Factors

 

51

Item 6.

 

Exhibits

 

92

 

 

Signatures

 

93

 

4


 

PART I — FINANCIAL INFORMATION

Item 1.

Financial Statements

Sage Therapeutics, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(in thousands, except share and per share data)

(Unaudited)

 

 

 

June 30,

2019

 

 

December 31,

2018

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

166,185

 

 

$

190,943

 

Marketable securities

 

 

1,070,364

 

 

 

731,833

 

Prepaid expenses and other current assets

 

 

27,021

 

 

 

21,919

 

Total current assets

 

 

1,263,570

 

 

 

944,695

 

Property and equipment, net

 

 

8,363

 

 

 

5,643

 

Restricted cash

 

 

2,367

 

 

 

2,367

 

Right of use operating asset

 

 

37,224

 

 

 

 

Other long-term assets

 

 

4,023

 

 

 

 

Total assets

 

$

1,315,547

 

 

$

952,705

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

12,431

 

 

$

34,036

 

Accrued expenses

 

 

58,912

 

 

 

51,994

 

Other current liabilities

 

 

7,610

 

 

 

 

Total current liabilities

 

 

78,953

 

 

 

86,030

 

Long-term lease operating liability, net of current portion

 

 

33,309

 

 

 

 

Other long-term liabilities

 

 

410

 

 

 

3,704

 

Total liabilities

 

 

112,672

 

 

 

89,734

 

Commitments and contingencies (Note 5)

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Preferred stock, $0.0001 par value per share; 5,000,000 shares authorized

   at June 30, 2019 and December 31, 2018; no shares issued or

   outstanding at June 30, 2019 and December 31, 2018

 

 

 

 

 

 

Common stock, $0.0001 par value per share; 120,000,000 shares authorized

   at June 30, 2019 and December 31, 2018; 51,472,137 and 46,891,296

   shares issued at June 30, 2019 and December 31, 2018; 51,469,104 and

   46,888,263 shares outstanding at June 30, 2019 and December 31, 2018

 

 

5

 

 

 

5

 

Treasury stock, at cost, 3,033 shares

   at June 30, 2019 and December 31, 2018

 

 

(400

)

 

 

(211

)

Additional paid-in capital

 

 

2,496,651

 

 

 

1,827,021

 

Accumulated deficit

 

 

(1,294,956

)

 

 

(963,329

)

Accumulated other comprehensive gain (loss)

 

 

1,575

 

 

 

(515

)

Total stockholders’ equity

 

 

1,202,875

 

 

 

862,971

 

Total liabilities and stockholders’ equity

 

$

1,315,547

 

 

$

952,705

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

5


 

Sage Therapeutics, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share data)

(Unaudited)

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2019

 

 

2018

 

 

2019

 

 

2018

 

Product revenue, net

 

$

519

 

 

$

 

 

$

519

 

 

$

 

Collaboration revenue

 

 

354

 

 

 

90,000

 

 

 

819

 

 

 

90,000

 

Total revenue

 

 

873

 

 

 

90,000

 

 

 

1,338

 

 

 

90,000

 

Operating costs and expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of goods sold

 

 

44

 

 

 

 

 

 

44

 

 

 

 

Research and development

 

 

89,059

 

 

 

68,980

 

 

 

175,457

 

 

 

118,250

 

Selling, general and administrative

 

 

88,227

 

 

 

43,167

 

 

 

172,146

 

 

 

72,016

 

Total operating costs and expenses

 

 

177,330

 

 

 

112,147

 

 

 

347,647

 

 

 

190,266

 

Loss from operations

 

 

(176,457

)

 

 

(22,147

)

 

 

(346,309

)

 

 

(100,266

)

Interest income, net

 

 

8,220

 

 

 

5,137

 

 

 

14,662

 

 

 

8,666

 

Other income, net

 

 

16

 

 

 

32

 

 

 

20

 

 

 

24

 

Net loss

 

$

(168,221

)

 

$

(16,978

)

 

$

(331,627

)

 

$

(91,576

)

Net loss per share—basic and diluted

 

$

(3.28

)

 

$

(0.36

)

 

$

(6.65

)

 

$

(2.02

)

Weighted average number of common shares

   outstanding—basic and diluted

 

 

51,257,640

 

 

 

46,541,716

 

 

 

49,882,377

 

 

 

45,439,666

 

Comprehensive loss:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(168,221

)

 

$

(16,978

)

 

$

(331,627

)

 

$

(91,576

)

Other comprehensive items:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized gain (loss) on marketable

   securities

 

 

1,681

 

 

 

40

 

 

 

2,090

 

 

 

(116

)

Total other comprehensive gain (loss)

 

 

1,681

 

 

 

40

 

 

 

2,090

 

 

 

(116

)

Total comprehensive loss

 

$

(166,540

)

 

$

(16,938

)

 

$

(329,537

)

 

$

(91,692

)

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

6


 

Sage Therapeutics, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(in thousands)

(Unaudited)

 

 

 

Six Months Ended June 30,

 

 

 

2019

 

 

2018

 

Cash flows from operating activities

 

 

 

 

 

 

 

 

Net loss

 

$

(331,627

)

 

$

(91,576

)

Adjustments to reconcile net loss to net cash used in operating

   activities:

 

 

 

 

 

 

 

 

Stock-based compensation expense

 

 

78,883

 

 

 

44,845

 

Premium on marketable securities

 

 

(1,887

)

 

 

(75

)

Amortization of discount on marketable securities

 

 

(4,973

)

 

 

(4,154

)

Depreciation

 

 

920

 

 

 

493

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Prepaid expenses and other current assets

 

 

(5,102

)

 

 

(25,091

)

Other long-term assets

 

 

(4,023

)

 

 

 

Right of use operating asset

 

 

4,713

 

 

 

 

Operating lease liabilities

 

 

(4,346

)

 

 

 

Accounts payable

 

 

(21,806

)

 

 

(903

)

Accrued expenses and other liabilities

 

 

5,970

 

 

 

(2,245

)

Net cash used in operating activities

 

 

(283,278

)

 

 

(78,706

)

Cash flows from investing activities

 

 

 

 

 

 

 

 

Proceeds from sales and maturities of marketable securities

 

 

588,652

 

 

 

263,460

 

Purchases of marketable securities

 

 

(918,233

)

 

 

(813,337

)

Purchases of property and equipment

 

 

(3,438

)

 

 

(1,054

)

Net cash used in investing activities

 

 

(333,019

)

 

 

(550,931

)

Cash flows from financing activities

 

 

 

 

 

 

 

 

Proceeds from stock option exercises and employee stock purchase

   plan issuances

 

 

31,282

 

 

 

19,402

 

Payment of employee tax obligations related to vesting of

   restricted stock units

 

 

(692

)

 

 

(904

)

Payments of offering costs

 

 

(328

)

 

 

(340

)

Proceeds from public offerings of common stock, net of commissions

   and underwriting discounts

 

 

561,277

 

 

 

631,494

 

Net cash provided by financing activities

 

 

591,539

 

 

 

649,652

 

Net increase (decrease) in cash, cash equivalents and restricted cash

 

 

(24,758

)

 

 

20,015

 

Cash, cash equivalents and restricted cash at beginning of period

 

 

193,310

 

 

 

307,084

 

Cash, cash equivalents and restricted cash at end of period

 

$

168,552

 

 

$

327,099

 

Supplemental disclosure of non-cash operating and investing activities

 

 

 

 

 

 

 

 

Purchases of property and equipment included in accounts payable

 

$

252

 

 

$

10

 

Right of use assets obtained in exchange for new operating lease liabilities

 

$

872

 

 

$

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 

7


 

Sage Therapeutics, Inc. and Subsidiaries

Consolidated Statements of Changes in Stockholders’ Equity

(in thousands, except share data)

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

Other

 

 

 

 

 

 

Total

 

 

 

Common Stock

 

 

Treasury Stock

 

 

Paid-in

 

 

Comprehensive

 

 

Accumulated

 

 

Stockholders’

 

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Income (Loss)

 

 

Deficit

 

 

Equity

 

Balances at December 31, 2017

 

 

42,002,934

 

 

$

5

 

 

 

960

 

 

$

(113

)

 

$

1,066,059

 

 

$

(29

)

 

$

(590,447

)

 

$

475,475

 

Issuance of common stock from exercise of

   stock options

 

 

402,227

 

 

 

 

 

 

 

 

 

 

 

 

11,727

 

 

 

 

 

 

 

 

 

11,727

 

Issuance of common stock under employee

   stock purchase plan

 

 

11,683

 

 

 

 

 

 

 

 

 

 

 

 

1,127

 

 

 

 

 

 

 

 

 

1,127

 

Purchase of treasury stock

 

 

 

 

 

 

 

 

554

 

 

 

(98

)

 

 

 

 

 

 

 

 

 

 

 

(98

)

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

15,549

 

 

 

 

 

 

 

 

 

15,549

 

Public offering of common stock, net of

   offering costs

 

 

4,032,012

 

 

 

 

 

 

 

 

 

 

 

 

631,154

 

 

 

 

 

 

 

 

 

631,154

 

Unrealized loss on available-for-sale securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(156

)

 

 

 

 

 

(156

)

Vesting of restricted stock units, net of employee

   tax obligations

 

 

9,442

 

 

 

 

 

 

 

 

 

 

 

 

(904

)

 

 

 

 

 

 

 

 

(904

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(74,598

)

 

 

(74,598

)

Balances at March 31, 2018

 

 

46,458,298

 

 

$

5

 

 

 

1,514

 

 

$

(211

)

 

$

1,724,712

 

 

$

(185

)

 

$

(665,045

)

 

$

1,059,276

 

Issuance of common stock from exercise of

   stock options

 

 

145,541

 

 

 

 

 

 

 

 

 

 

 

 

6,643

 

 

 

 

 

 

 

 

 

6,643

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

28,782

 

 

 

 

 

 

 

 

 

28,782

 

Unrealized loss on available-for-sale securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

40

 

 

 

 

 

 

40

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(16,978

)

 

 

(16,978

)

Balances at June 30, 2018

 

 

46,603,839

 

 

$

5

 

 

 

1,514

 

 

$

(211

)

 

$

1,760,137

 

 

$

(145

)

 

$

(682,023

)

 

$

1,077,763

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances at December 31, 2018

 

 

46,888,263

 

 

$

5

 

 

 

3,033

 

 

$

(211

)

 

$

1,827,021

 

 

$

(515

)

 

$

(963,329

)

 

$

862,971

 

Issuance of common stock from exercise of stock

   options

 

 

287,659

 

 

 

 

 

 

 

 

 

 

 

 

14,072

 

 

 

 

 

 

 

 

 

14,072

 

Issuance of common stock under employee

   stock purchase plan

 

 

16,398

 

 

 

 

 

 

 

 

 

 

 

 

1,799

 

 

 

 

 

 

 

 

 

1,799

 

Purchase of treasury stock

 

 

 

 

 

 

 

 

 

 

 

(189

)

 

 

 

 

 

 

 

 

 

 

 

(189

)

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

43,622

 

 

 

 

 

 

 

 

 

43,622

 

Public offering of common stock, net of offering costs

 

 

3,833,334

 

 

 

 

 

 

 

 

 

 

 

 

560,948

 

 

 

 

 

 

 

 

 

560,948

 

Unrealized gain on available-for-sale securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

409

 

 

 

 

 

 

409

 

Vesting of restricted stock units, net of employee

   tax obligations

 

 

8,518

 

 

 

 

 

 

 

 

 

 

 

 

(692

)